TSHR169 Antigen Specifically Binds to the Thyroid-stimulating Autoantibody, Representing an Effective Biomarker for Graves’ Disease

The thyroid-stimulating hormone receptor (TSHR) is one of the thyroid antigens responsible for Graves’ disease and acts as a biomarker for early detection. The purpose of this study was to computationally compare the effectiveness of TSHR56 and TSHR169 fragments in binding to the thyroid-stimulating...

Full description

Bibliographic Details
Main Authors: Zulkarnain Zulkarnain, Hidayat Sujuti, Djoko Wahono Soeatmadji, Didik Huswo Utomo, Aulanni’am Aulanni’am
Format: Article
Language:English
Published: Bulgarian Academy of Sciences 2019-03-01
Series:International Journal Bioautomation
Subjects:
Online Access:http://www.biomed.bas.bg/bioautomation/2019/vol_23.1/files/23.1_05.pdf
_version_ 1811333321519529984
author Zulkarnain Zulkarnain
Hidayat Sujuti
Djoko Wahono Soeatmadji
Didik Huswo Utomo
Aulanni’am Aulanni’am
author_facet Zulkarnain Zulkarnain
Hidayat Sujuti
Djoko Wahono Soeatmadji
Didik Huswo Utomo
Aulanni’am Aulanni’am
author_sort Zulkarnain Zulkarnain
collection DOAJ
description The thyroid-stimulating hormone receptor (TSHR) is one of the thyroid antigens responsible for Graves’ disease and acts as a biomarker for early detection. The purpose of this study was to computationally compare the effectiveness of TSHR56 and TSHR169 fragments in binding to the thyroid-stimulating human monoclonal autoantibody (M22) at the molecular level. The 3D model of M22 was obtained from RCSB (ID 3G04), while the TSHR antigen models were submitted to homology modeling using SWISSMODEL and PhyreV2.0 server to predict the protein structures. The model was validated by generating a Ramachandran plot with the RAMPAGE server. Prediction of the molecular interaction between TSHR and M22 was performed using the HADDOCK web server (version 2.2). Analysis of the binding affinity was conducted using the PRODIGY server. Interactions within the TSHR-M22 complex were analyzed using DIMPLOT. The antigen models had reliability scores of 100% and 97.7% for TSHR56 and TSHR169, respectively. The results of the molecular docking analysis revealed a better HADDOCK score for TSHR169 (-144.7 ± 2.4) compared to TSHR56 (-53.3 ± 10.1). However, the affinity of TSHR56 (-10.1 Kcal/mol) and TSHR169 (-10.2 Kcal/mol) were not significantly different. The results of the TSHR-M22 interaction specificity analysis suggested that TSHR169 is superior to TSHR56, as the number of interacting amino acids was comparable to the control (TSHR260-M22). It can be concluded that TSHR169 represents a specific full-length TSHR antigen and can be developed as biomarker for Graves’ disease.
first_indexed 2024-04-13T16:50:10Z
format Article
id doaj.art-88b6eeedf7fa47b18497ae455bfa7be4
institution Directory Open Access Journal
issn 1314-1902
1314-2321
language English
last_indexed 2024-04-13T16:50:10Z
publishDate 2019-03-01
publisher Bulgarian Academy of Sciences
record_format Article
series International Journal Bioautomation
spelling doaj.art-88b6eeedf7fa47b18497ae455bfa7be42022-12-22T02:38:57ZengBulgarian Academy of SciencesInternational Journal Bioautomation1314-19021314-23212019-03-01231516010.7546/ijba.2019.23.1.51-60TSHR169 Antigen Specifically Binds to the Thyroid-stimulating Autoantibody, Representing an Effective Biomarker for Graves’ DiseaseZulkarnain Zulkarnain0Hidayat SujutiDjoko Wahono SoeatmadjiDidik Huswo UtomoAulanni’am Aulanni’amBiochemistry and Biomolecular Department, Brawijaya University, Malang, IndonesiaThe thyroid-stimulating hormone receptor (TSHR) is one of the thyroid antigens responsible for Graves’ disease and acts as a biomarker for early detection. The purpose of this study was to computationally compare the effectiveness of TSHR56 and TSHR169 fragments in binding to the thyroid-stimulating human monoclonal autoantibody (M22) at the molecular level. The 3D model of M22 was obtained from RCSB (ID 3G04), while the TSHR antigen models were submitted to homology modeling using SWISSMODEL and PhyreV2.0 server to predict the protein structures. The model was validated by generating a Ramachandran plot with the RAMPAGE server. Prediction of the molecular interaction between TSHR and M22 was performed using the HADDOCK web server (version 2.2). Analysis of the binding affinity was conducted using the PRODIGY server. Interactions within the TSHR-M22 complex were analyzed using DIMPLOT. The antigen models had reliability scores of 100% and 97.7% for TSHR56 and TSHR169, respectively. The results of the molecular docking analysis revealed a better HADDOCK score for TSHR169 (-144.7 ± 2.4) compared to TSHR56 (-53.3 ± 10.1). However, the affinity of TSHR56 (-10.1 Kcal/mol) and TSHR169 (-10.2 Kcal/mol) were not significantly different. The results of the TSHR-M22 interaction specificity analysis suggested that TSHR169 is superior to TSHR56, as the number of interacting amino acids was comparable to the control (TSHR260-M22). It can be concluded that TSHR169 represents a specific full-length TSHR antigen and can be developed as biomarker for Graves’ disease.http://www.biomed.bas.bg/bioautomation/2019/vol_23.1/files/23.1_05.pdfGraves’ diseaseMolecular dockingThyroid-stimulating antibodyTSHR56TSHR169
spellingShingle Zulkarnain Zulkarnain
Hidayat Sujuti
Djoko Wahono Soeatmadji
Didik Huswo Utomo
Aulanni’am Aulanni’am
TSHR169 Antigen Specifically Binds to the Thyroid-stimulating Autoantibody, Representing an Effective Biomarker for Graves’ Disease
International Journal Bioautomation
Graves’ disease
Molecular docking
Thyroid-stimulating antibody
TSHR56
TSHR169
title TSHR169 Antigen Specifically Binds to the Thyroid-stimulating Autoantibody, Representing an Effective Biomarker for Graves’ Disease
title_full TSHR169 Antigen Specifically Binds to the Thyroid-stimulating Autoantibody, Representing an Effective Biomarker for Graves’ Disease
title_fullStr TSHR169 Antigen Specifically Binds to the Thyroid-stimulating Autoantibody, Representing an Effective Biomarker for Graves’ Disease
title_full_unstemmed TSHR169 Antigen Specifically Binds to the Thyroid-stimulating Autoantibody, Representing an Effective Biomarker for Graves’ Disease
title_short TSHR169 Antigen Specifically Binds to the Thyroid-stimulating Autoantibody, Representing an Effective Biomarker for Graves’ Disease
title_sort tshr169 antigen specifically binds to the thyroid stimulating autoantibody representing an effective biomarker for graves disease
topic Graves’ disease
Molecular docking
Thyroid-stimulating antibody
TSHR56
TSHR169
url http://www.biomed.bas.bg/bioautomation/2019/vol_23.1/files/23.1_05.pdf
work_keys_str_mv AT zulkarnainzulkarnain tshr169antigenspecificallybindstothethyroidstimulatingautoantibodyrepresentinganeffectivebiomarkerforgravesdisease
AT hidayatsujuti tshr169antigenspecificallybindstothethyroidstimulatingautoantibodyrepresentinganeffectivebiomarkerforgravesdisease
AT djokowahonosoeatmadji tshr169antigenspecificallybindstothethyroidstimulatingautoantibodyrepresentinganeffectivebiomarkerforgravesdisease
AT didikhuswoutomo tshr169antigenspecificallybindstothethyroidstimulatingautoantibodyrepresentinganeffectivebiomarkerforgravesdisease
AT aulanniamaulanniam tshr169antigenspecificallybindstothethyroidstimulatingautoantibodyrepresentinganeffectivebiomarkerforgravesdisease